MedPath

Nanjing Leads Biolabs Co., Ltd.

Nanjing Leads Biolabs Co., Ltd. logo
🇨🇳China
Ownership
Holding, Subsidiary
Established
2012-11-27
Employees
1
Market Cap
-
Website
http://leadsbiolabs.com

Clinical Trials

14

Active:0
Completed:3

Trial Phases

3 Phases

Phase 1:10
Phase 2:1
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (71.4%)
Not Applicable
3 (21.4%)
Phase 2
1 (7.1%)

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

First Posted Date
2025-08-08
Last Posted Date
2025-08-13
Lead Sponsor
Nanjing Leads Biolabs Co.,Ltd
Target Recruit Count
172
Registration Number
NCT07111546
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Jiangxi Cancer Hospital, Nanchang, Jiangxi, China

🇨🇳

Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China

and more 2 locations

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

Not Applicable
Not yet recruiting
Conditions
Advanced Melanoma
Interventions
First Posted Date
2025-08-01
Last Posted Date
2025-08-05
Lead Sponsor
Nanjing Leads Biolabs Co.,Ltd
Target Recruit Count
200
Registration Number
NCT07099430
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

and more 2 locations

A Phase Ib/Ⅱ Trial of LBL-024 in Combination With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Not Applicable
Not yet recruiting
Conditions
Ovarian Cancer
Interventions
Drug: LBL-024 Injection
First Posted Date
2025-06-29
Last Posted Date
2025-06-29
Lead Sponsor
Nanjing Leads Biolabs Co.,Ltd
Target Recruit Count
110
Registration Number
NCT07042802

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

First Posted Date
2025-01-20
Last Posted Date
2025-08-03
Lead Sponsor
Nanjing Leads Biolabs Co.,Ltd
Target Recruit Count
230
Registration Number
NCT06783647
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

and more 9 locations

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

First Posted Date
2023-12-06
Last Posted Date
2024-11-14
Lead Sponsor
Nanjing Leads Biolabs Co.,Ltd
Target Recruit Count
178
Registration Number
NCT06157827
Locations
🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

🇨🇳

Anhui Cancer Hospital, Hefei, Anhui, China

🇨🇳

Beijing GoBroad Hospital, Beijing, Beijing, China

and more 21 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

LBL-024 Bispecific Antibody Shows 75% Response Rate in Advanced Neuroendocrine Carcinoma Trial

Leads Biolabs' LBL-024, a first-in-class PD-L1/4-1BB bispecific antibody, achieved a 75% overall response rate in 52 patients with advanced extrapulmonary neuroendocrine carcinoma when combined with chemotherapy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.